Grant: Master's Award: Canada Graduate Research Scholarships - Master's program
University of British Columbia
$27,000.00
Novel 'Safety Switch' for CAR-T Cell Therapy
FY 2025-26
Summary
Chimeric antigen receptor (CAR) T cell therapy can treat blood cancers that failed to be treated with traditional therapies; however, a long-term side effect of CAR-T cell therapy is B-cell depletion induced by persistent CAR-T cells after therapeutic remission. B-cells are immune cells that produce antibodies to defend against infections. While this potential side effect is often “acceptable” in adult patients, pediatric patients are more vulnerable to B-cell aplasia, as it can damage their long-term immunity. Currently, B-cell depletion is treated by injections of supplemental antibodies to substitute the natural immune system; however, patient’s will require routine monitoring and injections while they have B-cell aplasia. This project aims to develop an antibody safety switch as a mitigation strategy to increase the safety of CAR-T cells for pediatric patients and minimize long-term side effects. The safety switch will target the unique binding site CAR-T cells utilize to identify and remove cancer cells, which should prevent off-target binding of the safety switch to healthy tissue. Mice will be immunized with the CAR-T cell binding site to produce antibodies against that sequence. The antibodies will be characterized for their specificity and efficacy to reduce CAR-T cells using patient blood samples. The most efficacious safety switch will be assessed in healthy mice treated with CAR-T cells to induce B-cell aplasia. We expect to observe CAR-T cell reduction post-safety switch injection, followed by B-cell recuperation. If approved for clinical application, the safety switch would improve post-therapy outcomes for pediatric patients, thereby increasing the implementation of CAR-T cell therapy to treat their cancers that have not responded to traditional therapy.
Department
Program
Master's Award: Canada Graduate Research Scholarships - Master's program
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
572853
Name
Burns Maria C
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Novel 'Safety Switch' for CAR-T Cell Therapy
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Antibodies; B-Cells; Car-T Persistence; Chimeric Antigen Receptor; Cytopenia; Gene Therapy; Immunotherapy; Leukemias; Pediatrics; T-Cells
Abstract
Chimeric antigen receptor (CAR) T cell therapy can treat blood cancers that failed to be treated with traditional therapies; however, a long-term side effect of CAR-T cell therapy is B-cell depletion induced by persistent CAR-T cells after therapeutic remission. B-cells are immune cells that produce antibodies to defend against infections. While this potential side effect is often “acceptable” in adult patients, pediatric patients are more vulnerable to B-cell aplasia, as it can damage their long-term immunity. Currently, B-cell depletion is treated by injections of supplemental antibodies to substitute the natural immune system; however, patient’s will require routine monitoring and injections while they have B-cell aplasia. This project aims to develop an antibody safety switch as a mitigation strategy to increase the safety of CAR-T cells for pediatric patients and minimize long-term side effects. The safety switch will target the unique binding site CAR-T cells utilize to identify and remove cancer cells, which should prevent off-target binding of the safety switch to healthy tissue. Mice will be immunized with the CAR-T cell binding site to produce antibodies against that sequence. The antibodies will be characterized for their specificity and efficacy to reduce CAR-T cells using patient blood samples. The most efficacious safety switch will be assessed in healthy mice treated with CAR-T cells to induce B-cell aplasia. We expect to observe CAR-T cell reduction post-safety switch injection, followed by B-cell recuperation. If approved for clinical application, the safety switch would improve post-therapy outcomes for pediatric patients, thereby increasing the implementation of CAR-T cell therapy to treat their cancers that have not responded to traditional therapy.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Burns, Maria C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~